| 重组人生长激素治疗肝硬化低蛋白血症的影响因素及意义 |
| |
| 引用本文： | 周梅花,孙大勇,赵亚刚,宋鸿,王卫卫,周兰.重组人生长激素治疗肝硬化低蛋白血症的影响因素及意义[J].现代消化及介入诊疗,2011,16(2):87-89. |
| |
| 作者姓名： | 周梅花 孙大勇 赵亚刚 宋鸿 王卫卫 周兰 |
| |
| 作者单位： | 广州军区广州总医院消化内科,510010 |
| |
| 摘 要： | 目的探讨重组人生长激素对不同血清白蛋白含量肝硬化患者低蛋白血症的临床疗效及意义。方法将92例血清白蛋白含量低于35g/L的肝硬化患者根据血清白蛋白含量分为3组：轻度低水平组（30.0～35.0g/L）、中度低水平组（25.0～30.0g/L）、重度低水平组（20.0～25.0g/L）,每组随机分为两组,治疗组给予重组人生长激素4IU肌注,1次/2日;对照组给予20%人血白蛋白100ml静滴,1次/2日,两组疗程均为30d。治疗组和对照组均给予相同方案的保肝、对症治疗。分别于治疗后15d、30d、60d、90d测定相应观察指标。结果治疗后30d两组患者血清白蛋白含量均上升,治疗组于治疗后第90d后仍维持高点水平,且肝功能好转,而对照组60d后白蛋白含量开始降低;血清白蛋白浓度大于25.0g/L时,治疗组观察指标改善尤为明显。结论重组人生长激素可明显提高肝硬化低蛋白血症患者血清白蛋白水平,中远期疗效好,并可改善肝功能;肝硬化患者血清白蛋白浓度对生长激素的疗效具有显著影响。
|
| 关 键 词： | 生长激素 肝硬化 低蛋白血症 |
Therapeutic effect of recombinant human growth hormone in the treatment of liver cirrhosis with different levels of hypoproteinemia |
| |
| ZHOU Mei-hua,SUN Da-yong,ZHAO Ya-gang,SONG Hong,WANG Wei-wei,ZHOU Lan.Therapeutic effect of recombinant human growth hormone in the treatment of liver cirrhosis with different levels of hypoproteinemia[J].Modern Digestion & Intervention,2011,16(2):87-89. |
| |
| Authors: | ZHOU Mei-hua SUN Da-yong ZHAO Ya-gang SONG Hong WANG Wei-wei ZHOU Lan |
| |
| Institution: | ZHOU Mei-hua,SUN Da-yong,ZHAO Ya-gang,SONG Hong,WANG Weiwei,ZHOU Lan.Department of Gastroenterology,Guangzhou General Hospital of Guangzhou Military Command,Guangzhou 510010,China |
| |
| Abstract: | Objective To investigate the therapeutic effect of recombinant human growth hormone (rhGH) in the treatment of liver cirrhosis with different levels of hypoproteinemia.Methods Ninety-two patients with liver cirrhosis and low serum albumin were divided to three groups on the basis of different levels of hypoproteinemia.Patients in each group were randomly assigned to receive intramuscular injection of 4 IU rhGH (treatment group) or intravenous injection of 100 ml 20% human serum albumin (control group) once ... |
| |
| Keywords: | Growth hormone Livercirrhosis Hypoproteinemia |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
